{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:06:57Z","timestamp":1790611617107,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258924"],"award-info":[{"award-number":["R01CA258924"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.009","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:27:55Z","timestamp":1752593275000},"page":"951-963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Resistance to Bruton Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"39","author":[{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2025.05.009_bib1","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.009_bib2","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.009_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.009_bib4","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.009_bib5","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ejh.14204","article-title":"Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variations","volume":"113","author":"Smith","year":"2024","journal-title":"Eur J Haematol"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.009_bib8","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-19-1009","article-title":"Decreased NOTCH1 activation correlates with response to ibrutinib in chronic lymphocytic leukemia","volume":"25","author":"Del","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.009_bib9","first-page":"2345","article-title":"Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia","volume":"106","author":"Del","year":"2021","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.009_bib10","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1158\/1078-0432.CCR-22-3217","article-title":"CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy","volume":"29","author":"Alsadhan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70008","article-title":"Molecular profiling identifies CD49d and CD79b as predictive markers for acquired acalabrutinib resistance in patients with chronic lymphocytic leukemia","volume":"43","author":"Bibikova","year":"2025","journal-title":"Hematol Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.009_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.009_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/bloodadvances.2021006211","article-title":"Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors","volume":"6","author":"Thompson","year":"2022","journal-title":"Blood Adv"},{"issue":"736","key":"10.1016\/j.hoc.2025.05.009_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"},{"key":"10.1016\/j.hoc.2025.05.009_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-025-06200-9","article-title":"Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors","author":"Garcia","year":"2025","journal-title":"Ann Hematol"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.009_bib16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTK(Cys481Ser) drives ibrutinib resistance via ERK1\/2 and protects BTK(wild-type) MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.009_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.009_bib18","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.009_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood.2019000854","article-title":"Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study","volume":"134","author":"Quinquenel","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.009_bib20","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.009_bib21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.27544","article-title":"Prevalence of BTK and PLCG2 mutations in CLL patients with disease progression on BTK inhibitor therapy: a meta-analysis","volume":"100","author":"Molica","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.009_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.2021015132","article-title":"Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients","volume":"140","author":"Black","year":"2022","journal-title":"Blood"},{"issue":"sup1","key":"10.1016\/j.hoc.2025.05.009_bib23","first-page":"S20","article-title":"Mutations detected in real world clinical sequencing during BTK inhibitor treatment in chronic lymphocytic leukemia (CLL)","volume":"64","author":"Mashima","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.009_bib24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2024-205557","article-title":"Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and by-pass signaling via MAPK pathway","volume":"144","author":"Terzi Di Bergamo","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.009_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173770","article-title":"FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia","volume":"134","author":"Ondrisova","year":"2024","journal-title":"J Clin Investig"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.009_bib26","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41375-024-02301-y","article-title":"Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia","volume":"38","author":"Pozzo","year":"2024","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.hoc.2025.05.009_bib27","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1182\/bloodadvances.2023012360","article-title":"Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib","volume":"8","author":"Aslan","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.009_bib28","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.009_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.009_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.009_bib32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1182\/blood-2024-198147","article-title":"Bruin CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"144","author":"Sharman","year":"2024","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.009_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupinan","year":"2021","journal-title":"Leukemia"},{"issue":"6682","key":"10.1016\/j.hoc.2025.05.009_bib34","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-22-0642","article-title":"Bruton's tyrosine kinase inhibitors with distinct binding modes reveal differential functional impact on B-Cell receptor signaling","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer Therapeut"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib36","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1182\/blood-2023-186052","article-title":"Understanding resistance mechanisms and growth kinetics of CLL treated with covalent and non-covalent BTK inhibitors","volume":"142","author":"Naeem","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.009_bib37","first-page":"1","article-title":"Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy","author":"Gruessner","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2025.05.009_bib38","author":"Wiestner"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2023-180143","article-title":"Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia patients: updated analysis from the BRUIN Study","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"issue":"387846","key":"10.1016\/j.hoc.2025.05.009_bib40","article-title":"Genomic evolution and resistance to pirtobrutinib in covalent BTK inhibitor (cBTKi) pre-treated chronic lymphocytic leukemia (CLL) patients: results from the phase I\/II BRUIN study","author":"Brown","year":"2023","journal-title":"EHA Library"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.009_bib41","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","article-title":"Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors","volume":"7","author":"Qi","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.009_bib42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2159-8290.CD-23-0670","article-title":"First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia and b-cell non-hodgkin lymphoma","volume":"14","author":"Woyach","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2025.05.009_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2019-127674","article-title":"Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.009_bib44","unstructured":"Ahn IE, Bruton\u2019s tyrosine kinase and phospholipase C-gamma 2 mutational profiles in pooled analysis of patients with chronic lymphocytic leukemia treated with ibrutinib. Presented at: XX International Workshop on Chronic Lymphocytic Leukemia (iwCLL); Boston, MA, USA, Available at: https:\/\/iwcll2023.eventscribe.net\/fsPopup.asp?PresentationID=1313422&mode=presInfo (Accessed 2 May 2025), 2023."},{"issue":"10","key":"10.1016\/j.hoc.2025.05.009_bib45","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.009_bib46","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/bloodadvances.2024014206","article-title":"Acquired mutations in patients with relapsed\/refractory CLL who progressed in the ALPINE study","volume":"9","author":"Brown","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.009_bib47","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022009366","article-title":"BTK mutations in patients with chronic lymphocytic leukemia (CLL) receiving tirabrutinib","author":"Jackson","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.05.009_bib48","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60470","article-title":"Differential impact of BTK active site inhibitors on the conformational state of full-length BTK","volume":"9","author":"Joseph","year":"2020","journal-title":"Elife"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.009_bib49","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and safety of the Bruton\u2019s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.009_bib50","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.009_bib51","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton tyrosine kinase (BTK) A428D confers resistance to BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"issue":"42","key":"10.1016\/j.hoc.2025.05.009_bib52","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:51:13Z","timestamp":1760503873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000814"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.009","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to Bruton Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}